President Droupadi Murmu launched a beacon of hope in the fight against cancer by unveiling India’s very own CAR T-cell therapy! This revolutionary treatment, a joint effort by IIT Bombay and the Tata Memorial Centre, is a major breakthrough that promises greater affordability and accessibility for cancer patients across the nation.
Making CAR T-Cell Therapy a Reality for All
CAR T-cell therapy has emerged as a powerful weapon against various cancers. This gene-based therapy involves modifying a patient’s T cells (immune system fighters) to target and destroy cancer cells. However, the high cost of this treatment has kept it out of reach for many.
NexCAR19: A Game Changer
India’s first indigenously-developed CAR T-cell therapy, NexCAR19, is set to change the game. Developed collaboratively by IIT Bombay and the Tata Memorial Centre, NexCAR19 is a shining example of the “Make in India” initiative. This revolutionary therapy is priced at a fraction of the cost compared to similar treatments available internationally, making it a much more viable option for cancer patients in India.
A New Dawn for Cancer Care
President Murmu lauded NexCAR19 as a “major breakthrough” and a testament to the brilliance of Indian scientists and doctors. This cost-effective therapy offers renewed hope for countless cancer patients who previously couldn’t afford such treatments.
Leaders in the Field of Cell and Gene Therapy
IIT Bombay Director Prof Subhasis Chaudhuri expressed his pride in this achievement, highlighting how NexCAR19 positions India at the forefront of cell and gene therapy. Sudeep Gupta, Director of the Tata Memorial Centre, echoed this sentiment, calling the creation of NexCAR19 a “historic milestone.”
Saving Lives and Offering Hope
Both President Murmu and Dr. Gupta emphasized the life-saving potential of NexCAR19. This groundbreaking therapy has the power to not only save countless lives but also bring immense relief to patients and their families.